Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Director Bernard Coulie of Septerna received a stock option grant on June 17, 2025, according to a Form 4 filing. The grant consists of 16,623 stock options with an exercise price of $10.24 per share.
Key details of the option grant:
- Exercise Price: $10.24 per share
- Expiration Date: June 16, 2035
- Vesting Schedule: Full vesting upon the earlier of (i) June 17, 2026 or (ii) the next annual stockholders meeting
- Vesting Condition: Subject to continued service with the company
This appears to be a standard director compensation grant. The filing was signed by Jeffrey Finer as attorney-in-fact on June 20, 2025. The transaction represents direct ownership of the derivative securities.
Director Abraham Bassan of Septerna received a stock option grant for 16,623 shares of common stock on June 17, 2025. The options were granted with an exercise price of $10.24 per share and will expire on June 16, 2035.
Key terms of the option grant:
- Full vesting occurs at the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on continued service with the company
- The options represent a new derivative security position, with direct ownership
This Form 4 filing, signed by Jeffrey Finer as attorney-in-fact on June 20, 2025, reports the transaction under Section 16(a) of the Securities Exchange Act of 1934. The grant appears to be part of the company's director compensation program.
Director Alan Ezekowitz of Septerna received a stock option grant on June 17, 2025, representing a significant insider transaction. Key details include:
- Granted 16,623 stock options to purchase common stock at an exercise price of $10.24 per share
- Options will vest in full upon the earlier of:
- June 17, 2026
- The company's next annual stockholders meeting
- Options expire on June 16, 2035
- Vesting is contingent on continued service with the company
This equity compensation grant aligns with standard director compensation practices and serves to align the director's interests with those of shareholders. The filing was executed by Jeffrey Finer as attorney-in-fact on June 20, 2025.
Septerna held its 2025 Annual Meeting of Stockholders on June 17, 2025 via virtual format. Of the total 44,515,703 eligible voting shares, 34,278,489 shares were represented, establishing a quorum.
Two key proposals were voted on:
- Proposal 1: Election of Class I Directors: - Abraham Bassan, M.S. elected with 29,320,969 votes in favor - Alan Ezekowitz, M.D., D.Phil. elected with 29,195,219 votes in favor
- Proposal 2: Ratification of Ernst & Young LLP as independent auditor was approved with 34,218,829 votes in favor, representing overwhelming support
The company, listed on Nasdaq Global Market under symbol SEPN, is classified as an emerging growth company. Both directors will serve three-year terms until the 2028 annual meeting.